The global advanced wound closure market is projected to grow from USD 18.47 billion in 2025 to USD 32.54 billion by 2035, at a CAGR of 6.9%. Growth is driven by increasing surgical procedures, rising chronic wounds and diabetes cases, and technological innovations in surgical sealants, hemostats, and tissue adhesives. North America leads the market while Asia Pacific shows the highest growth potential.

The global orthopedic implants market is valued at USD 52.86 billion in 2026 and is expected to reach USD 80.14 billion by 2034, growing at a 5.34% CAGR. North America leads the market while Asia-Pacific is the fastest-growing region. Joint reconstruction dominates by product type, with spinal implants showing significant growth potential. Key drivers include an aging population, rising musculoskeletal disorders, and technological innovations in 3D-printed and AI-enabled implants.

Integra LifeSciences reported Q3 2025 revenues of $402.1 million, a 5.6% increase from the previous year. The company saw healthy demand across its portfolio, with strong profitability driven by disciplined cost management and operational efficiencies.

The US breast reconstruction market is projected to grow from $1.02 billion in 2024 to $1.74 billion by 2033, driven by rising breast cancer incidences, improved surgical techniques, and increased insurance coverage.

The global craniomaxillofacial devices market is projected to grow from $1.8 billion in 2024 to $3.9 billion by 2034, driven by increased facial injuries, technological advancements, and minimally invasive surgical techniques.

Integra LifeSciences Holdings Corporation reported weaker-than-expected financial results for the first quarter of 2025, leading to a significant drop in its stock price. The Pomerantz Law Firm is investigating potential securities fraud or other unlawful business practices by the company and its officers.

Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (CAPR) after the company announced that the FDA will hold an advisory committee meeting for its Biologics License Application, causing the stock price to drop.

Cable One reported disappointing Q1 2025 earnings, missing analyst expectations and suspending its dividend. The stock price fell over 40% on this news, leading Pomerantz LLP to investigate potential securities fraud or other unlawful business practices by the company and its officers/directors.

Integra LifeSciences Holdings Corporation reported weaker-than-expected Q1 2025 earnings and issued a disappointing full-year guidance, leading to a 21% drop in its stock price. The Pomerantz Law Firm is investigating potential securities fraud or other unlawful business practices by the company.

Cable One reported disappointing Q1 2025 earnings, missing analyst expectations and suspending its dividend. The stock price fell over 40% on this news, leading Pomerantz LLP to investigate potential securities fraud or other unlawful business practices by the company and its officers/directors.

Grabar Law Office is investigating claims on behalf of long-term shareholders of Driven Brands, Holley, Integra LifeSciences, and Virtu Financial, alleging breaches of fiduciary duties by certain officers of these companies.

Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties. The investigation is related to a securities fraud class action complaint alleging that Integra misled investors about the quality control issues at its Boston facility, leading to a product recall and financial impact.